<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00522730</url>
  </required_header>
  <id_info>
    <org_study_id>SELLIFA-02</org_study_id>
    <secondary_id>B40320072194</secondary_id>
    <secondary_id>EudraCT n°2007-002940-86</secondary_id>
    <nct_id>NCT00522730</nct_id>
  </id_info>
  <brief_title>Safety and Tolerance on Lipids of Parenteral and Enteral Nutrition in Critically Ill Patients With Liver Failure</brief_title>
  <acronym>SELLIFA</acronym>
  <official_title>Sepsis, Endothelial Function, and Lipids in Critically Ill Patients With Liver Failure (SELLIFA). Randomized Controlled Trial Comparing the Tolerance on Lipids and Safety of Isocaloric Parenteral Nutrition With Enteral Nutrition.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the tolerance on lipid metabolism and the safety of&#xD;
      short-term parenteral nutrition as compared to enteral nutrition in critically ill patients&#xD;
      with liver failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An impaired lipid metabolism is often found in patients with liver disease and is assumed to&#xD;
      influence the prognosis. The central role of lipid metabolism in the pathophysiology of fatty&#xD;
      liver disease and steatohepatitis is well established. In cirrhotic patients, serum lipid&#xD;
      levels are mostly decreased and related to the severity of liver failure; in addition, the&#xD;
      structure and composition of lipoproteins differ from that of healthy individuals. A&#xD;
      reduction in high-density lipoproteins has been associated with higher cytokines levels and a&#xD;
      poorer clinical outcome in septic patients. Furthermore, the oxidative stress induced by&#xD;
      septic complications in critically ill patients with liver failure may lead to further&#xD;
      hepatocellular injury and activation of systemic inflammation cascade.&#xD;
&#xD;
      In this setting, the influence of nutrition on lipid metabolism may have an impact on the&#xD;
      severity of liver failure and associated complications. Although plasma clearance and&#xD;
      oxidation of lipids were considered to be normal in the majority of patients with cirrhosis,&#xD;
      most previous studies only reported the effects of an oral ingestion or parenteral infusion&#xD;
      of lipids during a few hours.&#xD;
&#xD;
      The present randomized controlled trial will be conducted in a subgroup of patients enrolled&#xD;
      in the SELLIFA-01 prospective study (NCT00488917). The purpose of the nutritional trial is to&#xD;
      determine the tolerance on lipid metabolism and the safety of isocaloric short-term&#xD;
      parenteral nutrition as compared to enteral nutrition in critically ill septic and non septic&#xD;
      patients with liver failure. The nutrition will be delivered continuously for 5 days and will&#xD;
      provide a daily energy supply corresponding to current resting energy expenditure as&#xD;
      determined by indirect calorimetry, with 35% of total energy requirements as lipids, 15% as&#xD;
      proteins (maximum 1.2g/kg ideal body weight/day), and 50% as dextrose. A tight glucose&#xD;
      control strategy will be implemented to avoid hyperglycemia.&#xD;
&#xD;
      The trial is designed to randomly assign 15 patients in each interventional group in order to&#xD;
      detect more than 25% increase in plasma triglycerides levels with 80% statistical power for&#xD;
      two-tailed type I error of 5%.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma concentration of triglycerides, total cholesterol, HDL-cholesterol, free fatty acids, apolipoproteins, lipoprotein (a)</measure>
    <time_frame>within 5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of hyperglycaemia</measure>
    <time_frame>within 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alteration of liver function</measure>
    <time_frame>within 5 and 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal intolerance</measure>
    <time_frame>within 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal bleeding</measure>
    <time_frame>within 5 and 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Septic complications</measure>
    <time_frame>within 5 and 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of new organ dysfunction</measure>
    <time_frame>within 5 and 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the intensive care unit (ICU)</measure>
    <time_frame>within 5 and 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>within 5 and 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Liver Failure</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parenteral nutrition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enteral nutrition</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Parenteral nutrition</intervention_name>
    <description>Duration : 5 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Enteral nutrition</intervention_name>
    <description>Duration : 5 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All consecutive patients with a diagnosis of chronic liver failure;&#xD;
&#xD;
          -  Planned total nutritional support;&#xD;
&#xD;
          -  Adult patient aged 18 years or above, and less than 85;&#xD;
&#xD;
          -  Admission to the ICU for an expected period of &gt; 24 hours;&#xD;
&#xD;
          -  Informed consent of the patient or nearest relative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Absolute contra-indications to enteral nutrition : total mechanical ileus, persistent&#xD;
             vomiting, high output fistulas, uncertain gastrointestinal anastomosis;&#xD;
&#xD;
          -  Absolute contra-indications to parenteral nutrition : severe hypertriglyceridemia &gt; 6&#xD;
             mmol/l (&gt; 545 mg/dL), severe diabetic ketoacidosis;&#xD;
&#xD;
          -  Age less than 18 years or more than 85;&#xD;
&#xD;
          -  Pregnancy, including HELLP syndrome;&#xD;
&#xD;
          -  Active malignancy with metastases (localized hepatocellular carcinoma is not an&#xD;
             exclusion criteria);&#xD;
&#xD;
          -  Systemic chemotherapy in the last 4 weeks (trans-arterial chemo-embolisation for&#xD;
             localized hepatocellular carcinoma is not an exclusion criteria);&#xD;
&#xD;
          -  Acquired immunodeficiency syndrome and antiretroviral therapy;&#xD;
&#xD;
          -  Refusal of the patient or nearest relative.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-François Laterre, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yvan Fleury, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departement of intensive care, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>August 29, 2007</study_first_submitted>
  <study_first_submitted_qc>August 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2007</study_first_posted>
  <last_update_submitted>September 2, 2009</last_update_submitted>
  <last_update_submitted_qc>September 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Pierre-François Laterre, MD</name_title>
    <organization>Cliniques universitaires Saint-Luc, Université Catholique de Louvain</organization>
  </responsible_party>
  <keyword>Liver failure</keyword>
  <keyword>Liver cirrhosis</keyword>
  <keyword>Parenteral nutrition</keyword>
  <keyword>Enteral nutrition</keyword>
  <keyword>Lipids</keyword>
  <keyword>Safety</keyword>
  <keyword>Drug tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

